MDxHealth is a diagnostics & research business based in the US. MDxHealth shares (MDXH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.87 – an increase of 19.11% over the previous week. MDxHealth employs 300 staff and has a trailing 12-month revenue of around $84.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.87 |
|---|---|
| 52-week range | $1.55 - $4.64 |
| 50-day moving average | $2.10 |
| 200-day moving average | $2.65 |
| Wall St. target price | $6.04 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.53 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.88 from 2024-11-22
| 1 week (2024-11-19) | 19.75% |
|---|---|
| 1 month (2024-10-25) | -10.48% |
| 3 months (2024-08-26) | -32.13% |
| 6 months (2024-05-24) | -31.14% |
| 1 year (2023-11-23) | N/A |
|---|---|
| 2 years (2022-11-23) | N/A |
| 3 years (2021-11-23) | N/A |
| 5 years (2019-11-23) | N/A |
| Revenue TTM | $84.7 million |
|---|---|
| Gross profit TTM | $19.2 million |
| Return on assets TTM | -11.02% |
| Return on equity TTM | -240.82% |
| Profit margin | -49.52% |
| Book value | $0.61 |
| Market Capitalization | $84.6 million |
TTM: trailing 12 months
We're not expecting MDxHealth to pay a dividend over the next 12 months.
You may also wish to consider:
MDxHealth's shares were split on a 1:10 basis on 13 November 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MDxHealth shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for MDxHealth shares which in turn could have impacted MDxHealth's share price.
Over the last 12 months, MDxHealth's shares have ranged in value from as little as $1.55 up to $4.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MDxHealth's is -393982.88. This would suggest that MDxHealth's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, MDxHealth has bucked the trend.
To put MDxHealth's beta into context you can compare it against those of similar companies.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.